NCT04415008View on ClinicalTrials.gov

Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

October 3, 2026

Study Completion Date

June 1, 2027

Conditions
CEBPA Double MutationAcute Myeloid Leukemia
Interventions
DRUG

HAD induction with intermediate dose cytarabine

daunorubicin,cytarabine,homoharringtonine

Trial Locations (1)

300020

HBDH, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER